ArticleBiochemistry and biophysics reports2026
The unseen impact of subclinical hypothyroidism on lipid profile and cardiovascular risk.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subclinical hypothyroidism (SCH), defined by elevated thyroid-stimulating hormone (TSH) with normal circulating thyroid hormones, is a common endocrine disorder that frequently remains clinically silent. Emerging evidence suggests that even mild thyroid dysfunction may influence lipid metabolism and contribute to early cardiovascular risk. However, the extent to which TSH levels reflect lipid abnormalities in SCH remains controversial. Objective: This study aimed to evaluate the influence of SCH on lipid metabolism and to determine whether TSH levels are associated with alterations in lipid profile parameters and atherogenic cardiovascular risk markers. Methods: A cross-sectional comparative study was conducted including 40 participants: 20 patients diagnosed with SCH and 20 euthyroid controls matched for demographic characteristics. Serum concentrations of TSH, free triiodothyronine (FT3), and free thyroxine (FT4) were measured alongside lipid profile parameters, including total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). The LDL/HDL ratio was calculated as an indicator of atherogenic cardiovascular risk. Independent sample Results: Individuals with SCH demonstrated significant lipid alterations compared with euthyroid controls. Triglyceride levels were significantly higher (165.7 ± 60.8 vs. 92.9 ± 39.8 mg/dL; Conclusion: SCH is associated with unfavorable lipid alterations characterized by elevated triglycerides, reduced HDL-C, and an increased LDL/HDL ratio, suggesting early atherogenic risk despite normal thyroid hormone levels. These findings highlight the importance of comprehensive lipid assessment in SCH and suggest that the LDL/HDL ratio may serve as a more sensitive indicator of cardiovascular risk than TSH alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.